Brief: CytRx receives written FDA communication regarding partial clinical hold for aldoxorubicin clinical trials

LadRx

03/12/2014 11:00

Dec 3 (Reuters) - CytRx Corp  CYTR.O : 
 * Receives written FDA communication regarding partial clinical hold for 
   aldoxorubicin clinical trials 
 * Expects to announce preliminary results from ongoing phase 2 clinical trial 
   of aldoxorubicin in kaposi's sarcoma in the first half of 2015 
 * Believes partial hold issue to be expeditiously resolved;enrollment 
   rates,timelines for ongoing trials to remain materially unchanged 
 * Says company continues to expect clinical trial timelines to remain 
   materially unchanged and expeditiously resolved 
 * Expects to announce preliminary results from ongoing phase 2 clinical trial 
   of aldoxorubicin in glioblastoma multiforme in first half of 2015 
 * Remains committed to completing enrollment of its ongoing pivotal global 
   phase 3 trial in second-line soft tissue sarcoma by the end of 2015 
 * Source text for Eikon  ID:nPn4Bl1D2  
 * Further company coverage  CYTR.O  
 
  ((Bengaluru Newsroom; +1 646 223 8780))